Thank you for subscribing!
Next Investors Archived Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Finfeed Archived Dec 17, 2019
Finfeed runs the ruler over the biotech stocks to watch in 2020.
Finfeed Archived Dec 11, 2019
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
Finfeed Archived Nov 29, 2019
The $3 million BPH Energy Ltd (ASX: BPH) has promising prospects with the ability to capitalise on the development of one or some of the assets held by Advent Energy.
Get expert stock analysis direct in your inbox
Archer Materials Limited (ASX:AXE) has informed the market that it will close its Share Purchase Plan (SPP) on Friday, December 6, 2019 at 5 PM eastern daylight saving time.
Finfeed Archived Nov 28, 2019
Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.
Finfeed Archived Nov 26, 2019
Archer Materials Limited (ASX:AXE) has progressed its graphene-based biosensor technology development by building a first-phase prototype device to test the printing and performance of graphene inks.
Next Investors Archived Nov 25, 2019
Archer Materials (ASX:AXE) announced the successful and scalable assembly of qubit array components of the 12CQ room-temperature qubit processor.
Finfeed Archived Nov 19, 2019
Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Finfeed Archived Oct 24, 2019
Redbubble closed up 22% to finish at $177.5c on $5.4 million stock traded. The reason: they released strategic and financial updates for the first quarter (1Q) ended 30 September 2019.
Finfeed Archived Oct 23, 2019
The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.
Finfeed Archived Oct 03, 2019
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.
Finfeed Archived Oct 02, 2019
Actinogen Medical (ASX:ACW) released extremely promising results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial.
Actinogen closed up 466% to finish at 5.1c on $15.8 million stock traded. The company announced results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.
Finfeed Archived Sep 24, 2019
Osteopore yesterday closed up 260% (yes that's right) to finish at 72.5c on $4.6 million stock traded. The reason: they listed. Osteopore is one of the hottest, if not the hottest, IPOs in the last few years.
Finfeed Archived Sep 23, 2019
Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.
Finfeed Archived Sep 19, 2019
Some of today’s stocks would love to be as hot as Jimi Hendrix in his prime. That’s certainly what they are aiming for.
Join Our Mailing List
